Banner
Molecular Therapy Laboratory

Molecular Therapy Laboratory

 

The MTL undertakes design and development of antisense compounds to modify gene expression. The MTL has a focus on rare inherited diseases, with a particular interest in neuromuscular disorders. The MTL researchers have expertise in: manipulating alternative splicing; antisense oligomer design and evaluation; synthesis of research grade antisense oligonucleotides; designing therapeutic strategies to a range of genetic disorder; and assessing genetic modifications in vitro and in vivo.

 

The CCG Molecular Therapy capabilities include:

 

  • Molecular Therapy capabilities
  • Cell banking
  • Oligomer design, evaluation and production
  • Transcript and mutation analysis
  • Protein expression analysis
  • Antisense oligonucleotide production
  • Molecular Genetic Testing
LATEST PUBLICATIONS See all
  • 24 July 2015

    The emperor's new dystrophin: finding sense in the noise

    READ MORE

  • 24 July 2015

    Editorial: medicinal chemistry of aptamers

    READ MORE